Intracerebral haemorrhage (ICH) · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral…
Summary of findings table ‐ Cilostazol showed no clear difference in intracerebral haemorrhage (ICH) compared with aspirin (low certainty).
1 finding from 1 review
Functional status ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental outcomes · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failed CPAP · preterm infants with apnea
It is very uncertain whether variable flow changes failed CPAP (defined as need for mechanical ventilation) compared with ventilator CPAP (very low certainty).
1 finding from 1 review
Mean apnoea events (apnoea > 20 seconds with or without bradycardia or desaturation) Mean per 4‐hour interval · preterm infants with apnea
1 finding from 1 review
Neurodevelopmental outcomes · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failed CPAP · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean apnoea events · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vessel patency (at end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review